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Abstract
Glioma is the most common form of primary brain tumor. Demographically, the risk of occurrence increases until old age.
Here we present a novel computational model to reproduce the probability of glioma incidence across the lifespan.
Previous mathematical models explaining glioma incidence are framed in a rather abstract way, and do not directly relate to
empirical findings. To decrease this gap between theory and experimental observations, we incorporate recent data on
cellular and molecular factors underlying gliomagenesis. Since evidence implicates the adult neural stem cell as the likely
cell-of-origin of glioma, we have incorporated empirically-determined estimates of neural stem cell number, cell division
rate, mutation rate and oncogenic potential into our model. We demonstrate that our model yields results which match
actual demographic data in the human population. In particular, this model accounts for the observed peak incidence of
glioma at approximately 80 years of age, without the need to assert differential susceptibility throughout the population.
Overall, our model supports the hypothesis that glioma is caused by randomly-occurring oncogenic mutations within the
neural stem cell population. Based on this model, we assess the influence of the (experimentally indicated) decrease in the
number of neural stem cells and increase of cell division rate during aging. Our model provides multiple testable
predictions, and suggests that different temporal sequences of oncogenic mutations can lead to tumorigenesis. Finally, we
conclude that four or five oncogenic mutations are sufficient for the formation of glioma.
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Introduction
Glioma is the most common form of primary brain tumor [1].
Glioma commonly manifests itself as a high-grade tumor called
glioblastoma, a highly malignant and invasive tumor with median
patient survival of 12 months from diagnosis; lower-grade gliomas
increase in malignancy over time, with associated increases in
mortality [2].
The cellular mechanisms giving rise to glioma are subject to
intense research. The incidence of glioma is not significantly
affected by environmental factors such as UV light and carcinogen
exposure, due to the protective influence of the thick skull and the
blood-brain barrier. In addition, there are no known heritable
factors in the risk of glioma occurrence. These tumors appear to
arise idiopathically in a random manner throughout the popula-
tion [3]. Hence, glioma formation is an ideal test-case for
investigating how fundamental mechanisms on the single-cell
level give rise to cancer.
Increasing age is strongly associated with higher incidence and
increased malignant grade for all grades and types of glioma [4,5].
Age is in fact the single most robust factor influencing glioma
incidence, malignancy, and patient survival [1,2,4]. Insights into
changes that occur in the aging brain and the cells that originate
the tumor are therefore essential for understanding this increased
risk of oncogenic transformation and tumorigenesis.
The putative cell-of-origin of glioma is the neural stem cell
(NSC), which normally gives rise to new neurons and glial cells in
the adult brain. Experimentally causing oncogenic mutations in
this lineage leads to the formation of malignant tumors [6–8], and
gliomas cluster near germinal centers of the brain [9]. Proliferative
cells within the tumor share immunomarkers with NSCs [10,11].
NSCs already exist in a proliferative state, are capable of
differentiating into glial cell types, and can migrate through tissue
[12,13]. Transplantation of oncogenically-transformed mouse
neural stem cells into syngeneic mice reliably leads to the
formation of a tumor which recapitulates the proliferative and
invasive phenotype of human glioma [14,15]. Together, these
studies strongly implicate the neural stem cell as the most likely
cell-of-origin of glioma. In this report we show that modeling the
accumulation of random mutations during cell division in this stem
cell population can predict glioma incidence across the lifespan in
the human population. In particular, we propose a model that
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accounts for differential weightage and temporal ordering of
oncogenic mutations.
Materials and Methods
The model includes empirical data collected through literature
review. The mutation frequency was taken directly from a
published estimate and assumed to be constant across the lifespan
[16]. A small subset of mutations were deemed to have oncogenic
potential in this cellular compartment while all other mutations are
assumed to be neutral for this cancer type [17]. In this approach,
we used the Poisson-approximation of a binomial distribution for
computing the probabilities to have x oncogenic mutations. First
we compute the expected number of genetic mutations a cell has
had at a certain age, and based on that then compute the
probability of having x oncogenic mutations. The mutation rate is
therefore independent of whether or not the gene is oncogenic.
The exponentially decreasing number of neural stem cells was
calculated across the lifespan based on the published data for
human tissue [18]. Results of electron microscopy-based charac-
terization is shown in Figure 3 of [18], which used 200 micron
thick sections. Results of immunohistochemistry-based character-
ization are shown in Figure 1 of [18], which used 30 micron thick
sections. These data are in agreement - *144 cells per 200
micron-thick section (averaging the two locations described above)
and *22 DCX+ cells per mm2 in a 30 micron-thick section
(estimated from the graph in Figure 1r of [18]). These data both
yield approximately 720 DCX+ cells per mm3. To estimate KI67+
proliferative cells, not DCX+ cells, we multiplied the values for
KI67+ cells from the relevant graph (Figure 1s of [18]) by 33, just
as we multiplied the values for the DCX+ cells from the other
graph (Figure 1r of [18]) by 33. This provides values per mm3. In
agreement with the data presented in Figures 1 and 3 of [18], their
Figure 2c shows that the tract is 1 mm 6 1 mm wide. It is also
10 mm long (the scale bar represents 500 microns). So the number
of KI67+ cells per mm3 is multiplied again by 10 to estimate the
total number of KI67+ cells. The graph of KI67+ cells at each
time point was then extrapolated to estimate this population across
the entire lifespan. Overall, we computed the number of NSCs at
birth to be 237600, which was used as the initial value of the
modeled number of NSCs during aging (N0).
The cell division rate was calculated in NSCs derived from the
young adult and aged adult mouse brain [13]. The number of cell
divisions in a given time was calculated from live-cell time-lapse
imaging over a 48 hour period. Actively-cycling young adult NSCs
divided 1.37 times in 48 hours while actively-cycling aged adult
NSCs divided 1.74 times in 48 hours. Adjusted for time, actively-
cycling young adult NSCs divide 251 times per year while actively-
cycling aged adult NSCs divide 318 times per year. For the
estimate that is incorporated in the model, we have used a linear
interpolation between these two numbers across the human
lifespan. These estimates were assumed relevant for the population
of NSCs in the adult human brain (Fig. 1).
The model was implemented in MATLAB (Mathworks Inc.). A
time step dt of 0.001 years was used for calculating the prevalence.
The computation of the incidence was done by computing the
numerical differential of the prevalence over time. Bootstrapping
was used to compute the 95 % confidence interval of the
incidence, as shown in Fig. S1. 1000 bootstrap samples of size
100 000 were computed.
Two of the model parameters (d describing exponential
decrease of NSCs with time and s included in Eq. 5) were not
assessed from experimental findings. Depending on r(t) and kmin,
different incidence curves are obtained (i.e. the absolute values and
the position of the curve peak were different). We have adapted s
and d for the different scenarios, in order for the incidence curve
to match with the demographic data [1]. A match could only be
obtained for kminw~4. In Fig. 2, s~1 and d~0:1067 were used
for the incidence curve based on kmin~3, while for kmin~4 we
used s~10 and d~0:028. For the simulations using kmin~5 and
kmin~6 we set s~7500, d~0:038 and s~10 000 000, d~0:0497,
respectively.
Results
To create our model, we included empirical data representing
age-related changes in neural stem cell number and behavior. A
population of neural stem cells is present in the human brain at
birth but declines exponentially thereafter [18]. Experiments in
rodents demonstrate that the exponential decline in neural stem
cell number continues across the lifespan [13,19]. This depletion
of the stem cell population is due to cell death and terminal
differentiation. We have therefore approximated the size of this
cell population (N(t)) with an exponential interpolation of the data
from the human brain. Further experiments have demonstrated
that the remaining population of NSCs in the aged brain have
dysregulated cell cycle kinetics [13]. Individual remaining stem
cells have an increased likelihood of re-entering the cell cycle,
resulting in an increased number of cell divisions in a given period
of time (r(t)). We have approximated this behavior using a linear
interpolation. Our model incorporates these empirically-deter-
mined changes in neural stem cell number and behavior (Fig. 1).
NSCs accumulate mutations in every cell cycle. The process of
genome replication during cell division is imperfect, as a certain
number of mutations occur and some of these mutations will
remain unrepaired. The number of mutations incurred during a
single cell division has been estimated [16]. According to their
assessment, we denote by m~10e{7 the probability for a gene in
the coding region to mutate due to a single cell division. No single
mutation leads to oncogenesis, so multiple hits are necessary for
complete oncogenic transformation [20,21]. Cancer is character-
ized by a number of cellular changes, including loss of cell cycle
control, self-sufficiency in growth factor signaling, resistance to
anti-growth signals, escape from apoptosis, invasion and neovas-
cularization [22]. When Hanahan and Weinberg first described
these hallmarks of cancer, they proposed that approximately six
mutations would be required to dysregulate all six of these cellular
activities [22]. Yet now researchers appreciate that mutation of a
single multi-functional protein can predispose alterations to
multiple cellular activities [14,23]. Since the cell is dependent
upon semi-redundant regulatory pathways to control cell cycle
progression and other activities [20], loss of one major tumor
suppressor is not sufficient to create a tumor [21] and multiple
regulators must be disrupted to achieve oncogenic transformation
[14,24]. Of the 18 440 (ntotal ) protein-encoding genes in the
human, 522 have a causal role in human cancer and nglioma~29 of
these (Table S1) have a demonstrated role in promoting
gliomagenesis [17]. We assessed how many mutations in this set
of oncogenes are required to achieve tumor formation. Based on
this minimum number of mutations (kmin), our model computes
the total probability for a single NSC to become oncogenically
transformed. This integrative probability is calculated by summing
up the individual probabilities according to the following equation:
p(t)~
X29
i~kmin
pi(t), ð1Þ
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where pi(t) denotes the probability for i oncogenic mutations to
have occurred at time t. We have estimated pi(t) using the
experimentally assessed parameters N(t), r(t) and m. Based on the
number of protein-coding and gliomagenesis-relevant genes, the
probability for any one of the 29 oncogenes to become mutated
from cell division is given by ponc~nglioma:m. Assuming that any
gene mutates with equal probability, the occurrence of oncogenic
mutations can be approximated by the binomial distribution. It
follows that pi(t) is given by:
pi(t)~
R(t)
i
 
:pionc
:(1{ponc)
R(t){i, ð2Þ
where R(t) is the number of cell divisions a NSC has undergone
until time t. It is computed by integrating the cell division rate r(t)
across the age span until time t.
Given that R(t) and ponc take sufficiently high (w100) and low
(v0:0001) values respectively, the Poisson distribution is well-
suited as an approximation for this otherwise computationally very
demanding formula:
pi(t)~
li
i!
:e{l, ð3Þ
with l(t)~R(t):ponc. The temporal sequence of oncogene
mutations has been shown to be an important factor in tumor
formation [25,26], and so we have also accounted for it in our
model. Given that there are i! possibilities for i mutations to occur,
Eq. 3 becomes:
pi(t)~
s
i!
li
i!
:e{l, ð4Þ
where the scalar value s represents the number of specific
mutational sequences necessary for oncogenic transformation. For
kmin~5, we find s~7500 to be an appropriate value in order for
the incidence curve to be in numerical accordance with the
demographic data (Fig. 2). This means that on average 7500
different sequences of mutations exist (for the different scenarios,
i.e. 5, 6,…, 29 oncogenes affected), which can ultimately lead to
oncogenic transformation.
The probability for a single cell to become oncogenically
transformed is denoted by p(t). Accordingly, the probability for
glioma formation overall is proportional to the probability that at
least one of all the NSC becomes transformed:
pglioma(t)~1{(1{p(t))
N(t), ð5Þ
where N(t)~N0e
{d:t is the estimated number of NSCs at time t.
Figure 1. Modeled number and cell division rate of NSCs. (A) Number of NSCs during aging. The initial number of cells was estimated based
on [18]. The number of NSCs is given by N(t)~N0e
{d:t using d~0:038. (B) Modeled cell division rate over time. As shown in [13], NSCs increase their
rate during aging. We have approximated this behavior using a linear interpolation from 251 to 318 divisions per cell and year.
doi:10.1371/journal.pone.0111219.g001
Figure 2. Influence of kmin on location of peak incidence.
Representative incidence curves for kmin~3 (magenta), kmin~4 (cyan),
kmin~5 (blue) and kmin~6 (green). Only for kmin§4 can the condition
of peak incidence at approximately 80 years be fulfilled. Incidence
curves generated by the model for kmin~4, 5 and 6 are in accordance
with the demographic data from [1] (red crosses: mean incidence of age
groups, red lines: spans of age groups), with kmin~6 yielding the best
fit. Confidence intervals are shown in Fig. S1.
doi:10.1371/journal.pone.0111219.g002
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Hence, the parameter d describes the decay of the NSC
population over time, and so is in principle directly relatable to
empirical data. We have adapted d such that the resulting
incidence curve matches the demographic data, while being
qualitatively in accordance with experimental findings in the
mouse [13,19].
The prevalence of glioma is then proportional to pglioma(t).
Since the units from the demographic datasets are with respect to
100 000 person-years, we compute the prevalence by multiplying
pglioma(t) by 100 000. From this, the incidence is computed by
calculating the derivative. Since there are various time-varying
parameters in the model, an analytical differentiation comprises a
too extensive formula. We therefore assess the incidence numer-
ically. The obtained incidence curve is shown in Fig. 2 and
resembles the demographic data.
Figure 3. Effect of increasing cell division rate. (A) Modeled incidence of glioma (green) under constant cell division rate (r(t)~251
divisions
year
).
Model parameters kmin~5, s~8800 and d~0:0333 were used in order to match with the demographic data (red crosses: mean incidence of age
groups, red lines: spans of age groups). The increasing proliferation rate of NSCs is therefore not a necessary condition for the incidence curve to
match the demographic data, since similar results are obtained after changes in the model parameters s and d . (B) Number of NSCs over time, as
used for the incidence curve shown in (A) (black) and for the scenario where cell division rate increases linearly (Fig. 2, blue). Small changes in the
number of NSCs over time are sufficient to make up for the constant cell division rate. It remains an empirical question which estimates of N(t) and
r(t) are correct in the adult human, since these are extrapolated from the model, the young human, and the aging rodent. (C) Incidence of glioma as
derived from our model, for increasing (blue) and constant (green) cell division rate during aging. Model parameters are the same (kmin~5, s~7500,
d~0:038). The green curve is the predicted incidence by the model if the proliferation rate was constant, and so leads an estimate of the net effect of
the increase. Overall, our model suggests that the increase in cell-cycle re-entry substantially increases glioma formation. (D) Prevalence of glioma for
increasing (blue) and constant (green) cell division rate. As shown in Fig. S2, the results are qualitatively confirmed also for kmin =4.
doi:10.1371/journal.pone.0111219.g003
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The actual incidence of glioma across age demographics has
been documented by The Central Brain Tumor Registry of the
United States [1]. We have used these published data to provide a
fit for the incidence and prevalence of glioma across the lifespan
(Fig. 2). The model parameters s and d were adapted in order to
match with these incidence rates. The incidence curves obtained
from our model for kmin~4, kmin~5 or kmin~6 resemble these
demographic data. Also for kminw6 is it possible to achieve
agreement, and so our model yields a lower bound for the number
of mutations required for oncogenic transformation. However,
with increasing kmin the model parameters s and d need to change
too. In particular, the parameter s strongly increases. For kmin~4,
kmin~5 and kmin~6 we find s~10, s~7500 and s~10 000 000
to be well-suited, respectively.
The biological meaning of parameter s in Eq. 4 is twofold. It
captures that different oncogenes can yield the same transforma-
tion hallmarks [6,24], and so multiple sequences of the same
length could give rise to glioma. Additionally, s accounts for the
possibility that different temporal sequences of the same oncogenes
could lead to glioma formation. In the classical multistage model,
there is only one temporal order that can achieve transformation.
Importantly, since s denotes an average number of mutations, it
could be different for different sequence lengths i. With increasing
i, si can grow exponentially because of the factorials in the
denominator of Eq. 4. For simplification and due to lack of
detailed empirical knowledge, we chose to use the same s for all
sequence lengths.
Since no studies in the human have directly demonstrated
increased cell division in NSCs, we have created a related model
that assumes no age-related changes in cell division rate, cell cycle
length or likelihood to re-enter cell cycle. This adjusted model
yields the same results in glioma incidence and required mutation
number if the exponential decrease in proliferative cell number is
adjusted accordingly (Fig. 3A). This age-related change is there-
fore not a necessary condition of the model. Future labelling
studies of the proliferative cell population in the human brain will
help to evaluate the relative accuracy of these two models.
Interestingly, the model quantifies the net effect of an increasing
cell division rate while the other parameters are the same (Fig.
3CD). These results suggest that this increase of cell division rate
almost doubles the occurrence of glioma.
Discussion
Mathematical modeling has been used to create predictions
regarding the growth of tumors [27,28] and response of individual
tumors to surgical resection or radiotherapy [29,30]. The
incidence of tumors in a human population has also been modeled
[31,32]. However these models of cancer incidence did not employ
empirical measures of age-related changes in cellular dynamics,
nor did they incorporate experimental knowledge on glioma-
related proto-oncogenes. Here we present a model to predict the
probability of glioma incidence across the lifespan based on neural
stem cell dynamics in the individual organism.
We find that a simple model using recent estimates of biological
parameters on the single-cell level can account for demographic
observations. Along these lines, we provide a modified and
extended version of the well-established Armitage-Doll model
[31]. In contrast to this classical approach, we do not restrict our
model to a specific number of oncogenic mutations. Instead, we
account for all the numbers of oncogenic mutations that possibly
can occur (i.e. mutations of kmin to 29 oncogenes, see Eq. 1). Our
model therefore does not rely on the (experimentally unsupported)
assumption of the classical Armitage-Doll model that only a
specific number of oncogenes must be mutated for oncogenic
transformation.
Since the parameters of our model have a direct biological
meaning, further biological data can be incorporated and
predictions can be made. For example, previous theories have
yielded various estimates for the minimal number of oncogenic
mutations required for carcinogenesis [33–35]. Notably, we come
to the conclusion that a minimum of 4 or 5 oncogenic mutations is
sufficient for tumorigenesis, in contrast to 6-7 mutations as
implicated by the classical Armitage-Doll model [31] and as
predicted by Hanahan and Weinberg [22]. kmin~5 is higher than
experimental results which demonstrate that NSCs can be
oncogenically transformed successfully with only three oncogenic
mutations specifically affecting the PTEN, p53 and Rb pathways
[14,24,36]. However, many human gliomas regardless of grade
demonstrate 5 mutations, namely affecting EGFR, PTEN,
P16INK4A, TP53 and MDM2 [3]. Therefore our model is in line
with empirical studies on the number of mutations required to
achieve oncogenic transformation. Many mutations affecting
tumor suppressor pathways will cause a cell to undergo
senescence, slowing the cell division rate and increasing the
likelihood of apoptosis. Very few sequences of mutation are likely
to bypass this protective response. So it is easy to imagine that few
scenarios (s~10) are compatible with a low number of mutations
achieving oncogenic transformation (kmin~4), while more scenar-
ios (s~7500) can achieve oncogenic transformation with a larger
number of mutations (kmin~5). Considering that different
oncogenic mutations yield the same hallmark, and that multiple
temporal sequences of the same mutations could yield the same
result, we find s~7500 more plausible than s~10. This model
therefore supports the conclusion that five oncogenic mutations
are sufficient to achieve oncogenic transformation and initiate
gliomagenesis.
Our model accounts for the possibility that some oncogenes,
due to more interactions, play a more central role than others [37].
Therefore, fewer mutations of such hub genes might be sufficient
for the formation of glioma. It is possible that altered function of
such hub genes could lead to genomic instability and increased
mutation rate. However, one assumption in our model is the stable
accumulation of mutations in every cell cycle. While this number
of mutations have been estimated in proliferative cell types [16],
this rate may indeed depend on prior changes. With age, the
genome becomes more unstable due to shortened telomeres,
increased mutation load and chromosomal abnormalities [38]. All
of these changes could increase the likelihood of mutations or
disrupt the efficacy of repair mechanisms. The net mutations
incurred during each division may therefore increase with age.
However any age-related changes to the mutation rate depending
on prior mutation load have not been empirically determined so
we were unable to incorporate this age-related factor into our
calculations. We have therefore estimated that the mutation rate
remains constant across the lifespan.
However our model does allow us to incorporate different
weightage for mutations, i.e. that some mutations are less likely to
co-exist than others, as has been established by the Cancer
Genome Atlas effort (http://cancergenome.nih.gov/) [21,25]. In
Eq. 4 the denominator increases much faster than the nominator
with the length of the modeled sequence of oncogenes, and so long
sequences are unlikely to occur. Hence, mutational combinations
that are included only in the long sequences are unlikely to co-exist
overall.
In light of evidence that a temporal sequence of mutations may
be crucial in tumorigenesis [25,26], it is notable that our model
considers variation in the number and order of oncogenic
Modeling the Origins of Glioma
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mutations needed to invoke glioma formation. Our model thus
usefully explores the relationship between these experimentally
tractable variables, particularly kmin, d , s, N(t) and r(t).
Similar to previous researchers [32], we have included an age-
related decline in the number of proliferative cells, which is
responsible for the characteristic peak of the incidence at 80 years.
In contrast to their linear decrease, we model an exponential
decrease of the proliferative pool which matches better with
experimental findings in this cell population [13,18,19]. In
addition, we employ empirically-derived results to estimate cell
cycle length [12], the mutation rate during each cell cycle [16] and
the fraction of genes that promote oncogenic transformation upon
mutation ([17] and Table S1). Together, these data can be used to
predict the age-associated incidence of glioma in the human
population [1] without the need to assert differential susceptibility
throughout the population which is not supported by biological
evidence [39].
It is possible that other cell types besides the neural stem cell
give rise to glioma. One recent study demonstrated that mature
cells such as neurons can be forced to undergo oncogenic
transformation using cell-specific targeting of two major tumor
suppressor pathways [36], however it is not clear that such
mutations could randomly occur in a post-mitotic cell population.
Alternatively, glial progenitor cells within the white matter have
been proposed to be the true glioma cell-of-origin [40,41].
Empirical data on these cells are scarcer, so we are currently
unable to estimate the size of this population and the rate of glial
progenitor cell division across the lifespan (key variables for
implementing this model). Future studies may help to address
whether the cell cycle kinetics of this population can also predict
actual glioma incidence in the human population. Variability in
the cellular origin as well as the underlying genetic lesions of
glioma could in part explain the extraordinary heterogeneity in
this tumor type. Yet the evidence most strongly implicates the
multi-potent neural stem cell as the most likely cell of origin, so we
have focused on this cell type in our model.
There is evidence to suggest the molecular pathogenesis of high-
grade gliomas (presenting as primary glioblastoma) is different to
that of low-grade gliomas (presenting as grade II-III astrocytoma
or oligodendroglioma, often progressing to secondary glioblasto-
ma). These two types of brain tumor have different genetic and
epigenetic profiles, with different initiating mutations [42]. In the
future, this model could be adapted to include such different
constraints on molecular pathogenesis to distinguish between the
incidence rates of low-grade and high-grade glioma.
Overall, we provide a model that uses experimentally obtained
parameters on neural stem cell proliferation and yields results
which match with actual demographic data in the human
population. We demonstrate the consistency of our model which
incorporates estimates of neural stem cell number, cell division
rate, mutation rate and number of oncogenes. Importantly, our
model supports the hypothesis that glioma is caused by randomly
occurring oncogenic mutations within the neural stem cell
population of the adult brain.
Supporting Information
Figure S1 Confidence intervals for modeled incidence.
95 % confidence intervals (shaded) for the modeled incidence rates
during aging, as computed by bootstrapping. The modeled
incidence curve (blue line) is the same as shown in Fig. 2 using
(A) kmin~4, s~10 and d~0:028, (B) kmin~5, s~7500 and
d~0:038 and (C) kmin~6, s~10 000 000 and d~0:0497.
(PDF)
Figure S2 Effect of increasing cell division rate for
scenario with kmin~4. (A) Modeled incidence of glioma (black)
under constant cell division rate (r(t)~251
divisions
year
). Model
parameters kmin~4, s~10:2 and d~0:0233 were used in order to
match with the demographic data (red crosses: mean incidence of
age groups, red lines: spans of age groups). The increasing
proliferation rate of NSCs is therefore not a necessary condition
for the incidence curve to match the demographic data, since
similar results are obtained after changes in the model parameters
s and d . (B) Number of NSCs over time, as used for the incidence
curve shown in (A) (black) and for the scenario where cell division
rate increases linearly (Fig. 2, cyan). Small changes in the number
of NSCs over time are sufficient to make up for the constant cell
division rate. It remains an empirical question which estimates of
N(t) and r(t) are correct in the adult human, since these are
extrapolated from the model, the young human, and the aging
rodent. (C) Incidence of glioma as derived from our model, for
increasing (cyan) and constant (green) cell division rate during
aging. Model parameters are the same (kmin~4, s~10, d~0:028).
The green curve is the predicted incidence by the model if the
proliferation rate was constant, and so leads an estimate of the net
effect of the increase. Overall, as for kmin~5 our model suggests
that the increase in cell-cycle re-entry substantially increases
glioma formation. (D) Prevalence of glioma for increasing (cyan)
and constant (green) cell division rate.
(TIFF)
Table S1 Proto-oncogenes implicated in glioma forma-
tion. Information on the 29 proto-oncogenes that have been
implicated in the formation of glioma. The COSMIC Cancer
Gene Census is a regularly-updated catalogue of somatic cell
mutations causally implicated in cancer: http://cancer.sanger.ac.
uk/cosmic/census. Of all genes listed, we have selected genes with
a known role in glioma (including subtypes such as glioblastoma,
astrocytoma, oligodendroglioma). An additional 6 genes were
listed in the COSMIC gene database as being implicated in ‘‘other
tumor types’’. These genes, KRAS, MYC, CDKN2A(p16),
CDKN2A(p14), CTNNB1(beta-catenin), and ERBB2(HER2),
have indeed been implicated in gliomagenesis in other studies
[43–46], so we have included them in this list. The probability of
any one of the oncogenes being mutated is equivalent to
ponc~nglioma:m, where nglioma is the number of oncogenes involved
in glioma formation and m is the probability for genetic mutation
due to a single cell division.
(PDF)
Acknowledgments
This work is dedicated to Thomas Lo¨tsch, who deceased after his combat
against cancer. His inspirational spirit and zest for life will prevail.
We thank Peter Taylor, Yujiang Wang and Fre´de´ric Zubler for helpful
suggestions to the manuscript.
Author Contributions
Conceived and designed the experiments: RB ES. Performed the
experiments: RB. Analyzed the data: RB ES. Contributed reagents/
materials/analysis tools: RB MK ES. Wrote the paper: RB MK ES.
Modeling the Origins of Glioma
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e111219
References
1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical
report: primary brain and central nervous system tumors diagnosed in the united
states in 2005–2009. Neuro-Oncol 14: v1–v49.
2. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival
rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
J Neuropathol Exp Neurol 64: 479–489.
3. Ostrom QT, Barnholtz-Sloan JS (2011) Current state of our knowledge on brain
tumor epidemiology. Curr Neurol Neurosci Rep 11: 329–335.
4. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG (2010) Prevalence
estimates for primary brain tumors in the united states by age, gender, behavior,
and histology. Neuro-Oncol 12: 520–527.
5. Barker FG, Chang SM, Larson DA, Sneed PK, Wara WM, et al. (2001) Age and
radiation response in glioblastoma multiforme. Neurosurgery 49: 1288–1298.
6. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, et al. (2000) Combined
activation of ras and akt in neural progenitors induces glioblastoma formation in
mice. Nat Genet 25: 55–57.
7. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, et al. (2009)
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic
tumor suppressor mouse model. Cancer Cell 15: 45–56.
8. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, et al. (2009) Expression of
mutant p53 proteins implicates a lineage relationship between neural stem cells
and malignant astrocytic glioma in a murine model. Cancer Cell 15: 514–526.
9. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, et al. (2007) Relationship of
glioblastoma multiforme to neural stem cell regions predicts invasive and
multifocal tumor phenotype. Neuro-Oncol 9: 424–429.
10. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, et al. (2004) Isolation
of cancer stem cells from adult glioblastoma multiforme. Oncogene 23: 9392–
9400.
11. Stiles CD, Rowitch DH (2008) Glioma stem cells: a midterm exam. Neuron 58:
832–846.
12. Stoll EA, Cheung W, Mikheev AM, Sweet IR, Bielas JH, et al. (2011) Aging
neural progenitor cells have decreased mitochondrial content and lower
oxidative metabolism. J Biol Chem 286: 38592–38601.
13. Stoll EA, Habibi BA, Mikheev AM, Lasiene J, Massey SC, et al. (2011)
Increased re-entry into cell cycle mitigates age-related neurogenic decline in the
murine subventricular zone. Stem Cells 29: 2005–2017.
14. Mikheev AM, Stoll EA, Mikheeva SA, Maxwell JP, Jankowski PP, et al. (2009) A
syngeneic glioma model to assess the impact of neural progenitor target cell age
on tumor malignancy. Aging Cell 8: 499–501.
15. Mikheev AM, Ramakrishna R, Stoll EA, Mikheeva SA, Beyer RP, et al. (2012)
Increased age of transformed mouse neural progenitor/stem cells recapitulates
age-dependent clinical features of human glioma malignancy. Aging Cell 11:
1027–1035.
16. Frank SA, Nowak MA (2004) Problems of somatic mutation and cancer.
Bioessays 26: 291–299.
17. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The cosmic
(catalogue of somatic mutations in cancer) database and website. Br J Cancer
91: 355–358.
18. Sanai N, Nguyen T, Ihrie RA, Mirzadeh Z, Tsai HH, et al. (2011) Corridors of
migrating neurons in the human brain and their decline during infancy. Nature
478: 382–386.
19. Ahlenius H, Visan V, Kokaia M, Lindvall O, Kokaia Z (2009) Neural stem and
progenitor cells retain their potential for proliferation and differentiation into
functional neurons despite lower number in aged brain. J Neurosci 29: 4408–
4419.
20. Stoll EA, Horner PJ, Rostomily RC (2013) The impact of age on oncogenic
potential: tumor-initiating cells and the brain microenvironment. Aging Cell 12:
733–741.
21. Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zindy F, et al.
(2006) Loss of p53 induces changes in the behavior of subventricular zone cells:
implication for the genesis of glial tumors. J Neurosci 26: 1107–1116.
22. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
23. Strano S, Dell’Orso S, Di Agostino S, Fontemaggi G, Sacchi A, et al. (2007)
Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212–2219.
24. Chow LM, Endersby R, Zhu X, Rankin S, Qu C, et al. (2011) Cooperativity
within and among pten, p53, and rb pathways induces high-grade astrocytoma
in adult brain. Cancer Cell 19: 305–316.
25. Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N (2011) The
temporal order of genetic and pathway alterations in tumorigenesis. PLoS ONE
6: e27136.
26. Guo J, Guo H, Wang Z (2014) Inferring the temporal order of cancer gene
mutations in individual tumor samples. PLoS ONE 9: e89244.
27. Anderson AR, Weaver AM, Cummings PT, Quaranta V (2006) Tumor
morphology and phenotypic evolution driven by selective pressure from the
microenvironment. Cell 127: 905–915.
28. Choe SC, Zhao G, Zhao Z, Rosenblatt JD, Cho HM, et al. (2011) Model for in
vivo progression of tumors based on co-evolving cell population and vasculature.
Sci Rep 1: 31.
29. Swanson K, Rostomily R, Alvord E (2008) A mathematical modelling tool for
predicting survival of individual patients following resection of glioblastoma: a
proof of principle. Br J Cancer 98: 113–119.
30. Rockne R, Rockhill J, Mrugala M, Spence A, Kalet I, et al. (2010) Predicting the
efficacy of radiotherapy in individual glioblastoma patients in vivo: a
mathematical modeling approach. Phys Med Biol 55: 3271–3285.
31. Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage
theory of carcinogenesis. Br J Cancer 8: 1–12.
32. Pompei F, Wilson R (2002) A quantitative model of cellular senescence influence
on cancer and longevity. Toxicol Ind Health 18: 365–376.
33. Armitage P, Doll R (1957) A two-stage theory of carcinogenesis in relation to the
age distribution of human cancer. Br J Cancer 11: 161–169.
34. Fisher J (1958) Multiple-mutation theory of carcinogenesis. Nature 181: 651–
652.
35. Armitage P, Doll R (1961) Stochastic models for carcinogenesis. In: Proceedings
of the fourth Berkeley symposium on mathematical statistics and probability.
Berkeley: University of California Press, volume 4, pp.9–38.
36. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, et al. (2012)
Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in
mice. Science 338: 1080–1084.
37. Jeong H, Mason SP, Baraba´si AL, Oltvai ZN (2001) Lethality and centrality in
protein networks. Nature 411: 41–42.
38. Bailey KJ, Maslov AY, Pruitt SC (2004) Accumulation of mutations and somatic
selection in aging neural stem/progenitor cells. Aging Cell 3: 391–397.
39. Ritter G, Wilson R, Pompei F, Burmistrov D (2003) The multistage model of
cancer development: some implications. Toxicol Ind Health 19: 125–145.
40. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, et al. (2011) Mosaic
analysis with double markers reveals tumor cell of origin in glioma. Cell 146:
209–221.
41. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, et al. (2006) Glial
progenitors in adult white matter are driven to form malignant gliomas by
platelet-derived growth factor-expressing retroviruses. J Neurosci 26: 6781–
6790.
42. Ohgaki H, Kleihues P (2013) The definition of primary and secondary
glioblastoma. Clin Cancer Res 19: 764–772.
43. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, et al. (2012)
Prospective, high-throughput molecular profiling of human gliomas. J Neur-
ooncol 110: 89–98.
44. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, et al. (2014) Molecular
subtypes of glioblastoma are relevant to lower grade glioma. PloS ONE 9:
e91216.
45. Waage IS, Vreim I, Torp SH (2013) C-erbB2/HER2 in human gliomas,
medulloblastomas, and meningiomas: A minireview. Int J Surg Pathol:
1066896913492196.
46. Li J, Guo G, Li J, Hao J, Zhang J, et al. (2014) The expression and significance of
dishevelled in human glioma. J Surg Res: 10.1016/j.jss.2014.06.034.
Modeling the Origins of Glioma
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e111219
